Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.39 |
| ▸ | GJB2 | P29033 | 2/20 | 0.35 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | CDC25B | P30305 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26812522 | 0.91 | PDE2A (0.45) | PDE2AHTR1AHSPA5GJB2TACR2 | |
| SCHEMBL21137107 | 0.91 | PDE2A (0.45) | PDE2AHTR1AHSPA5GJB2TACR2 | |
| SCHEMBL29788347 | 0.86 | PDE2A (0.41) | PDE2AHTR1AGJB2TACR2CA1 | |
| SCHEMBL17453485 | 0.86 | PDE2A (0.41) | PDE2AHTR1AGJB2TACR2CA1 | |
| SCHEMBL27424648 | 0.82 | PDE2A (0.48) | PDE2AHTR1AHSPA5GJB2CA1 | |
| SCHEMBL17479350 | 0.82 | PDE2A (0.38) | PDE2AHTR1ATACR2PTPN1CDC25B | |
| SCHEMBL21880601 | 0.80 | HSPA5 (0.38) | PDE2AHTR1AHSPA5GJB2CA1 | |
| SCHEMBL17465437 | 0.79 | PDE2A (0.33) | PDE2AHSPA5 | |
| SCHEMBL17479377 | 0.77 | HTR1A (0.41) | PDE2AHTR1ATACR2CA1CA2 | |
| SCHEMBL17453458 | 0.77 | HTR1A (0.41) | PDE2AHTR1ATACR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023650-A1 | 4'-SUBSTITUTED-FURO[3,2-D]PYRIMIDINE AND -PYRROLO[3,2- D]PYRIMIDINE DERIVATIVES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3693367-B1 | THIENO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3174870-B1 | THIENO [3,2-D]PYRIMIDINES, FURO [3,2,D]PYRIMIDINES AND PYRROLO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190194223-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9828388-B2 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194223-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | DPYD, TYMS, TYMP | PDE2A 2339/4885HTR1A 1743/4885HSPA5 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.